비만대사연구학술지 (Archives of Obesity and Metabolism)

  • 제2권2호
  • /
  • Pages.54-63
  • /
  • 2023
  • /
  • 2951-0333(pISSN)
  • /
  • 2951-0597(eISSN)
대한가정의학회 비만대사증후군연구회 ( The Study of Obesity and Metabolic Syndrome, KAFM)
권호 표지
DOI QR코드

DOI QR Code

체중과 심혈관 질환에 대한 폐경기 호르몬 요법의 효과

Menopausal Hormone Therapy for Preventing Weight Gain and Cardiovascular Disease

  • 윤영숙 (인제대학교 일산백병원 가정의학과)
  • Yeong Sook Yoon (Department of Family Medicine, Inje University Ilsan Paik Hospital)
  • 투고 : 2023.10.06
  • 심사 : 2023.12.07
  • 발행 : 2023.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Estrogen is crucial in regulating food intake, energy expenditure, glucose metabolism, and lipid metabolism. During menopause, the decline in estrogen levels predisposes women to weight gain, abdominal obesity, insulin resistance, type 2 diabetes, hypertension, and cardiovascular disease (CVD). Menopausal hormone therapy (MHT) prevents weight gain, improves lipid metabolism by lowering low-density lipoprotein cholesterol while raising high-density lipoprotein cholesterol, and delays the onset of type 2 diabetes in menopausal women. The effect of MHT on CVD in menopausal women remains controversial. The Women's Health Initiative study was terminated prematurely after it revealed that hormone administration increased the risk of myocardial infarction, stroke, and thromboembolism. However, some studies have found that MHT had no effect or decreased the risk of CVD. The inconsistent results were likely due to multiple factors, including the timing of hormone therapy initiation, duration of therapy, type and dosage, and presence or absence of CVD risk factors at the start of treatment. Despite its benefits in terms of managing weight gain and reducing the risk of type 2 diabetes, dyslipidemia, and CVD associated with obesity, it is not recommended as the primary therapy for weight loss or diabetes prevention. MHT is primarily indicated for postmenopausal women, who are likely to benefit from its potential to prevent weight gain and improve lipid metabolism.

키워드

참고문헌

  1. Hewitt SC, Korach KS. Estrogen receptors: new directions in the new millennium. Endocr Rev 2018;39:664-75. https://doi.org/10.1210/er.2018-00087
  2. Xu Y, Nedungadi TP, Zhu L, et al. Distinct hypothalamic neurons mediate estrogenic effects on energy homeostasis and reproduction. Cell Metab 2011;14:453-65. https://doi.org/10.1016/j.cmet.2011.08.009
  3. Titolo D, Cai F, Belsham DD. Coordinate regulation of neuropeptide Y and agouti-related peptide gene expression by estrogen depends on the ratio of estrogen receptor (ER) alpha to ERbeta in clonal hypothalamic neurons. Mol Endocrinol 2006;20:2080-92. https://doi.org/10.1210/me.2006-0027
  4. Diano S, Kalra SP, Sakamoto H, Horvath TL. Leptin receptors in estrogen receptor-containing neurons of the female rat hypothalamus. Brain Res 1998;812:256-9. https://doi.org/10.1016/S0006-8993(98)00936-6
  5. Lindell K, Bennett PA, Itoh Y, Robinson IC, Carlsson LM, Carlsson B. Leptin receptor 5'untranslated regions in the rat: relative abundance, genomic organization and relation to putative response elements. Mol Cell Endocrinol 2001;172:37-45. https://doi.org/10.1016/S0303-7207(00)00382-8
  6. Asarian L, Geary N. Estradiol enhances cholecystokinin-dependent lipid-induced satiation and activates estrogen receptoralpha-expressing cells in the nucleus tractus solitarius of ovariectomized rats. Endocrinology 2007;148:5656-66. https://doi.org/10.1210/en.2007-0341
  7. Vogel H, Wolf S, Rabasa C, et al. GLP-1 and estrogen conjugate acts in the supramammillary nucleus to reduce food-reward and body weight. Neuropharmacology 2016;110(Pt A):396-406. https://doi.org/10.1016/j.neuropharm.2016.07.039
  8. Martinez de Morentin PB, Gonzalez-Garcia I, Martins L, et al. Estradiol regulates brown adipose tissue thermogenesis via hypothalamic AMPK. Cell Metab 2014;20:41-53. https://doi.org/10.1016/j.cmet.2014.03.031
  9. Sievers W, Rathner JA, Kettle C, Zacharias A, Irving HR, Green RA. The capacity for oestrogen to influence obesity through brown adipose tissue thermogenesis in animal models: a systematic review and meta-analysis. Obes Sci Pract 2019;5:592-602. https://doi.org/10.1002/osp4.368
  10. Homma H, Kurachi H, Nishio Y, et al. Estrogen suppresses transcription of lipoprotein lipase gene. Existence of a unique estrogen response element on the lipoprotein lipase promoter. J Biol Chem 2000;275:11404-11. https://doi.org/10.1074/jbc.275.15.11404
  11. Jeong S, Yoon M. 17β-estradiol inhibition of PPARγ-induced adipogenesis and adipocyte-specific gene expression. Acta Pharmacol Sin 2011;32:230-8. https://doi.org/10.1038/aps.2010.198
  12. Zhang R, Su D, Zhu W, et al. Estrogen suppresses adipogenesis by inhibiting S100A16 expression. J Mol Endocrinol 2014;52:235-44. https://doi.org/10.1530/JME-13-0273
  13. Gormsen LC, Host C, Hjerrild BE, et al. Estradiol acutely inhibits whole body lipid oxidation and attenuates lipolysis in subcutaneous adipose tissue: a randomized, placebo-controlled study in postmenopausal women. Eur J Endocrinol 2012;167:543-51. https://doi.org/10.1530/EJE-12-0422
  14. Lindberg UB, Crona N, Silfverstolpe G, Bjorntorp P, Rebuffe-Scrive M. Regional adipose tissue metabolism in postmeno-pausal women after treatment with exogenous sex steroids. Horm Metab Res 1990;22:345-51. https://doi.org/10.1055/s-2007-1004917
  15. Katzer K, Hill JL, McIver KB, Foster MT. Lipedema and the potential role of estrogen in excessive adipose tissue accumulation. Int J Mol Sci 2021;22:11720.
  16. Blouin K, Boivin A, Tchernof A. Androgens and body fat distribution. J Steroid Biochem Mol Biol 2008;108:272-80. https://doi.org/10.1016/j.jsbmb.2007.09.001
  17. Park YM, Erickson C, Bessesen D, Van Pelt RE, Cox-York K. Age- and menopause-related differences in subcutaneous adipose tissue estrogen receptor mRNA expression. Steroids 2017;121:17-21. https://doi.org/10.1016/j.steroids.2017.03.001
  18. Pedersen SB, Kristensen K, Hermann PA, Katzenellenbogen JA, Richelsen B. Estrogen controls lipolysis by up-regulating alpha2A-adrenergic receptors directly in human adipose tissue through the estrogen receptor alpha. Implications for the female fat distribution. J Clin Endocrinol Metab 2004;89:1869-78. https://doi.org/10.1210/jc.2003-031327
  19. Wakatsuki A. [Hormone replacement Up-to-date. Effects of estrogen replacement therapy on lipid metabolism]. Clin Calcium 2007;17:1366-71. Japanese.
  20. Shen M, Shi H. Sex hormones and their receptors regulate liver energy homeostasis. Int J Endocrinol 2015;2015:294278.
  21. Fatima LA, Campello RS, Barreto-Andrade JN, et al. Estradiol stimulates adipogenesis and Slc2a4/GLUT4 expression via ESR1-mediated activation of CEBPA. Mol Cell Endocrinol 2019;498:110447.
  22. Barros RP, Machado UF, Warner M, Gustafsson JA. Muscle GLUT4 regulation by estrogen receptors ERbeta and ERalpha. Proc Natl Acad Sci U S A 2006;103:1605-8. https://doi.org/10.1073/pnas.0510391103
  23. Gregorio KCR, Laurindo CP, Machado UF. Estrogen and glycemic homeostasis: the fundamental role of nuclear estrogen receptors ESR1/ESR2 in glucose transporter GLUT4 regulation. Cells 2021;10:99.
  24. Alonso-Magdalena P, Ropero AB, Carrera MP, et al. Pancreatic insulin content regulation by the estrogen receptor ER alpha. PLoS One 2008;3:e2069.
  25. Tiano JP, Mauvais-Jarvis F. Importance of oestrogen receptors to preserve functional β-cell mass in diabetes. Nat Rev Endocrinol 2012;8:342-51. https://doi.org/10.1038/nrendo.2011.242
  26. Handgraaf S, Dusaulcy R, Visentin F, Philippe J, Gosmain Y. 17-β Estradiol regulates proglucagon-derived peptide secretion in mouse and human α- and L cells. JCI Insight 2018;3:e98569.
  27. Cervellati C, Bergamini CM. Oxidative damage and the pathogenesis of menopause related disturbances and diseases. Clin Chem Lab Med 2016;54:739-53. https://doi.org/10.1515/cclm-2015-0807
  28. Davis SR, Baber RJ. Treating menopause - MHT and beyond. Nat Rev Endocrinol 2022;18:490-502. https://doi.org/10.1038/s41574-022-00685-4
  29. Greendale GA, Sternfeld B, Huang M, et al. Changes in body composition and weight during the menopause transition. JCI Insight 2019;4:e124865.
  30. Ambikairajah A, Walsh E, Tabatabaei-Jafari H, Cherbuin N. Fat mass changes during menopause: a metaanalysis. Am J Obstet Gynecol 2019;221:393-409.e50. https://doi.org/10.1016/j.ajog.2019.04.023
  31. Davis SR, Castelo-Branco C, Chedraui P, et al. Understanding weight gain at menopause. Climacteric 2012;15:419-29. https://doi.org/10.3109/13697137.2012.707385
  32. Lovejoy JC, Champagne CM, de Jonge L, Xie H, Smith SR. Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes (Lond) 2008;32:949-58. https://doi.org/10.1038/ijo.2008.25
  33. Karvonen-Gutierrez C, Kim C. Association of mid-life changes in body size, body composition and obesity status with the menopausal transition. Healthcare (Basel) 2016;4:42.
  34. Pu D, Tan R, Yu Q, Wu J. Metabolic syndrome in menopause and associated factors: a meta-analysis. Climacteric 2017;20:583-91. https://doi.org/10.1080/13697137.2017.1386649
  35. Samargandy S, Matthews KA, Brooks MM, et al. Abdominal visceral adipose tissue over the menopause transition and carotid atherosclerosis: the SWAN heart study. Menopause 2021;28:626-33. https://doi.org/10.1097/GME.0000000000001755
  36. Margolis KL, Bonds DE, Rodabough RJ, et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia 2004;47:1175-87. https://doi.org/10.1007/s00125-004-1448-x
  37. Kanaya AM, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/ progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003;138:1-9. https://doi.org/10.7326/0003-4819-138-1-200301070-00005
  38. Jensen LB, Vestergaard P, Hermann AP, et al. Hormone replacement therapy dissociates fat mass and bone mass, and tends to reduce weight gain in early postmenopausal women: a randomized controlled 5-year clinical trial of the Danish Osteoporosis Prevention Study. J Bone Miner Res 2003;18:333-42. https://doi.org/10.1359/jbmr.2003.18.2.333
  39. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995;273:199-208. https://doi.org/10.1001/jama.273.3.199
  40. Black DR, Minkin MJ, Graham S, Bernick B, Mirkin S. Effects of combined 17β-estradiol and progesterone on weight and blood pressure in postmenopausal women of the REPLENISH trial. Menopause 2020;28:32-9. https://doi.org/10.1097/GME.0000000000001659
  41. Yuan Q, Santos HO, Alshahrani MS, Baradwan S, Ju H. Does tibolone treatment have favorable effects on obesity, blood pressure, and inflammation? A meta-analysis of randomized controlled trials. Steroids 2022;178:108966.
  42. Black D, Messig M, Yu CR, et al. The effect of conjugated estrogens/bazedoxifene therapy on body weight of postmenopausal women: pooled analysis of five randomized, placebo-controlled trials. Menopause 2016;23:376-82. https://doi.org/10.1097/GME.0000000000000541
  43. Papadakis GE, Hans D, Gonzalez Rodriguez E, et al. Menopausal hormone therapy is associated with reduced total and visceral adiposity: the OsteoLaus cohort. J Clin Endocrinol Metab 2018;103:1948-57. https://doi.org/10.1210/jc.2017-02449
  44. Javed AA, Mayhew AJ, Shea AK, Raina P. Association between hormone therapy and muscle mass in postmenopausal women: a systematic review and meta-analysis. JAMA Netw Open 2019;2:e1910154.
  45. Norman RJ, Flight IH, Rees MC. Oestrogen and progestogen hormone replacement therapy for peri-menopausal and postmenopausal women: weight and body fat distribution. Cochrane Database Syst Rev 2000;(2):CD001018.
  46. Manson JE, Rimm EB, Colditz GA, et al. A prospective study of postmenopausal estrogen therapy and subsequent incidence of non-insulin-dependent diabetes mellitus. Ann Epidemiol 1992;2:665-73. https://doi.org/10.1016/1047-2797(92)90011-E
  47. Salpeter SR, Walsh JM, Ormiston TM, Greyber E, Buckley NS, Salpeter EE. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 2006;8:538-54. https://doi.org/10.1111/j.1463-1326.2005.00545.x
  48. Mauvais-Jarvis F, Manson JE, Stevenson JC, Fonseca VA. Menopausal hormone therapy and type 2 diabetes prevention: evidence, mechanisms, and clinical implications. Endocr Rev 2017;38:173-88. https://doi.org/10.1210/er.2016-1146
  49. Cui W, Zhao L. The influence of 17β-estradiol plus norethisterone acetate treatment on markers of glucose and insulin metabolism in women: a systematic review and meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne) 2023;14:1137406.
  50. Mumusoglu S, Yildiz BO. Metabolic syndrome during menopause. Curr Vasc Pharmacol 2019;17:595-603. https://doi.org/10.2174/1570161116666180904094149
  51. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 2001;75:898-915. https://doi.org/10.1016/S0015-0282(01)01699-5
  52. Nie G, Yang X, Wang Y, et al. The effects of menopause hormone therapy on lipid profile in postmenopausal women: a systematic review and meta-analysis. Front Pharmacol 2022;13:850815.
  53. Tao W, Cai X, Al Masri MK, et al. The effect of transdermal 17β-estradiol combined with norethisterone acetate treatment on the lipid profile in postmenopausal women: a meta-analysis and systematic review of randomized controlled trials. Steroids 2022;185:109061.
  54. Lv C, Zhang W, Tan X, et al. The effect of tibolone treatment on lipid profile in women: a systematic review and dose-response meta-analysis of randomized controlled trials. Pharmacol Res 2021;169:105612.
  55. Kim JE, Choi J, Park J, Shin A, Choi NK, Choi JY. Effects of menopausal hormone therapy on cardiovascular diseases and type 2 diabetes in middle-aged postmenopausal women: analysis of the Korea National Health Insurance Service Database. Menopause 2021;28:1225-32. https://doi.org/10.1097/GME.0000000000001848
  56. Carrasquilla GD, Berglund A, Gigante B, et al. Does menopausal hormone therapy reduce myocardial infarction risk if initiated early after menopause? A population-based case-control study. Menopause 2015;22:598-606. https://doi.org/10.1097/GME.0000000000000354
  57. Carrasquilla GD, Frumento P, Berglund A, et al. Postmenopausal hormone therapy and risk of stroke: a pooled analysis of data from population-based cohort studies. PLoS Med 2017;14:e1002445.
  58. Hodis HN, Mack WJ. The timing hypothesis and hormone replacement therapy: a paradigm shift in the primary prevention of coronary heart disease in women. Part 1: comparison of therapeutic efficacy. J Am Geriatr Soc 2013;61:1005-10. https://doi.org/10.1111/jgs.12140
  59. Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials. JAMA 2017;318:927-38. https://doi.org/10.1001/jama.2017.11217
  60. L'hermite M, Simoncini T, Fuller S, Genazzani AR. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review. Maturitas 2008;60:185-201. https://doi.org/10.1016/j.maturitas.2008.07.007
  61. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 2013;310:1353-68. https://doi.org/10.1001/jama.2013.278040
  62. Smith NL, Blondon M, Wiggins KL, et al. Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens. JAMA Intern Med 2014;174:25-31. https://doi.org/10.1001/jamainternmed.2013.11074
  63. Peeyananjarassri K, Baber R. Effects of low-dose hormone therapy on menopausal symptoms, bone mineral density, endometrium, and the cardiovascular system: a review of randomized clinical trials. Climacteric 2005;8:13-23. https://doi.org/10.1080/13697130400012288
  64. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;135:939-53. https://doi.org/10.7326/0003-4819-135-11-200112040-00005
  65. Angerer P, Stork S, Kothny W, Schmitt P, von Schacky C. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomized, controlled trial. Arterioscler Thromb Vasc Biol 2001;21:262-8. https://doi.org/10.1161/01.ATV.21.2.262
  66. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001;345:1243-9. https://doi.org/10.1056/NEJMoa010534